Why Cassava Sciences Stock Is Sinking Today
Shares of Cassava Sciences (NASDAQ: SAVA) were 5.3% lower as of 11:05 a.m. ET on Monday after falling as much as 19% earlier in the morning. The decline came on the heels of the federal indictment on Friday of Hoau-Yan Wang, a former consultant to Cassava.
Wang was accused of fraud related to grant applications made to the U.S. National Institutes of Health (NIH) for work on Cassava's experimental drug simufilam. These grants led to awards of roughly $16 million from the NIH between 2017 and 2021 to Wang and Cassava.
Cassava has revealed that some government agencies have asked for information and documents. The company cooperated with these inquiries. Cassava has not been charged with any misconduct at this point, although the biotech acknowledged in its more recent 10-K filing, "We cannot predict the outcome or impact of these ongoing matters, including whether a government agency may pursue an enforcement action against us or others."
Source Fool.com
National Cinemedia Inc. Stock
Our community is currently high on National Cinemedia Inc. with 4 Buy predictions and 0 Sell predictions.
With a target price of 7 € there is potential for a 2169.78% increase which would mean more than doubling the current price of 0.31 € for National Cinemedia Inc..